Bayer's Adempas gets EU approval nod
This article was originally published in Scrip
Just a week after Japan's Ministry of Health, Labour and Welfare (MHLW) granted approval to Bayer Healthcare's Adempas (riociguat), the product has been given the go-ahead by the EU's CHMP.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.